Radionetics Oncology and Eli Lilly Collaborate to Develop Small Molecule Radiopharmaceuticals
Shots:
- Radionetics Oncology has entered into a strategic collaboration with Eli Lilly to advance their G protein-coupled receptor (GPCR) targeting small molecule radiopharmaceuticals for treating solid tumors
- As per the agreement, Radionetics obtained a payment of $140M upfront in cash while Eli Lilly received an exclusive right to acquire Radionetics for an aggregate of $1B post exercise period
- Radionetics will develop a novel pipeline of GPCR targeting small molecule radioligand therapeutics by leveraging its discovery platform during the exercise period
Ref: Aktis Oncology | Image: Aktis Oncology
Related News:- Aktis Oncology and Eli Lilly Collaborate to Discover and Develop Novel Anticancer Radiopharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
